Edition:
United States

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

13.32EUR
17 Aug 2018
Change (% chg)

€-0.06 (-0.45%)
Prev Close
€13.38
Open
€13.38
Day's High
€13.48
Day's Low
€13.13
Volume
57,842
Avg. Vol
168,091
52-wk High
€19.42
52-wk Low
€8.92

Latest Key Developments (Source: Significant Developments)

Medigene AG Says ‍Planned 2018 EBITDA Loss Of EUR 21 - 23 Mln​
Thursday, 22 Mar 2018 02:30am EDT 

March 22 (Reuters) - Medigene AG ::PTA-NEWS: MEDIGENE AG: MEDIGENE PUBLISHES 2017 ANNUAL REPORT AND ANNOUNCES START OF CLINICAL TRIAL WITH TCR IMMUNOTHERAPY MDG1011.‍TOTAL REVENUES INCREASED BY 17%​.‍RAISED 2017 GUIDANCE MET, EBITDA LOSS LOWER THAN FORECASTED; LOSS REDUCED BY 2%​.‍STARTING PHASE I/II CLINICAL TRIAL WITH TCR IMMUNE CELL THERAPY MDG1011​.‍PATIENT RECRUITMENT COMPLETED FOR PHASE I/II STUDY WITH DC VACCINES​.‍COMPANY EXPECTS TO GENERATE TOTAL REVENUE OF BETWEEN EUR 7.5 - 9.5 M IN 2018​.‍PLANNED 2018 EBITDA LOSS OF EUR 21 - 23 M​.  Full Article

Medigene Receives Approvals For First Clinical Trial With MDG1011
Wednesday, 21 Feb 2018 01:30am EST 

Feb 21 (Reuters) - Medigene AG ::SAYS RECEIVES APPROVALS FOR ITS FIRST CLINICAL TRIAL WITH TCR THERAPY MDG1011.SAYS PAUL-EHRLICH-INSTITUTE AND THE RELEVANT ETHICS COMMITTEE HAVE APPROVED STUDY DESIGN OF PHASE I/II CLINICAL TRIAL WITH MDG1011​.‍SAYS EXPECTS TO START TRIAL WITHIN COMING WEEKS​.  Full Article

Medigene Strengthens Its Patent Portfolio With US Patent On Tagged TCR
Thursday, 1 Feb 2018 01:30am EST 

Feb 1 (Reuters) - MEDIGENE AG ::MEDIGENE STRENGTHENS ITS PATENT PORTFOLIO WITH A US PATENT ON A TAGGED TCR.  Full Article

Medigene Sells US-Rights For Veregen, Raises 2017 Guidance
Tuesday, 5 Dec 2017 10:30am EST 

Dec 5 (Reuters) - MEDIGENE AG ::PTA-ADHOC: MEDIGENE AG: MEDIGENE SELLS US-RIGHTS FOR VEREGEN® AND RAISES FINANCIAL GUIDANCE 2017.EXPECTS REVENUES OF EUR 10.5-11.5 M INSTEAD OF EUR 8-10 M AS PREVIOUSLY GUIDED.EXPECTS 2017 EBITDA-LOSS OF EUR 14-15 M INSTEAD OF EUR 16-18 M.EXPECTS 2017 CASH UTILIZATION OF EUR 20-22 M INSTEAD OF EUR 23-27 M.  Full Article

Medigene says 9M immunotherapy revenue 3.4 mln eur
Thursday, 9 Nov 2017 01:30am EST 

Nov 9 (Reuters) - Medigene :Says confirms its financial guidance for 2017.Says 9M revenue from core business immunotherapies (bluebird bio partnership) of eur 3.435 million.Says 9M total revenue eur 7.176 million (9M 2016: eur 7.052 million).Says 9M EBITDA loss increased as planned to eur 10.143 million (9M 2016: eur 9.095 million).  Full Article

Medigene to issue new shares to settle Trianta milestone payment
Thursday, 7 Sep 2017 12:00pm EDT 

Sept 7 (Reuters) - Medigene AG :Announces issuance and number of new shares to settle last Trianta milestone payment.Says 2 million euro milestone payment for achievement of third milestone for Trianta acquisition will be settled by issuance of new shares.Says to issue 182,335 new shares to former contributing shareholders of Medigene Immunotherapies GmbH.Says with this third and final milestone payment, the total purchase price of approx. 10 million euros will have been entirely settled.Says subscribers of new shares agreed to a lockup period of 14 months.  Full Article

Medigene H1 total revenue at EUR 4.9 mln​
Thursday, 3 Aug 2017 01:30am EDT 

Aug 3 (Reuters) - MEDIGENE AG :H1 ‍REVENUE FROM CORE BUSINESS IMMUNOTHERAPIES (BLUEBIRD BIO PARTNERSHIP) AMOUNTS TO EUR2,252 K (6M 2016: EUR0 K)​.‍H1 TOTAL REVENUE OF EUR4,915 K (6M 2016: EUR5,470 K)​.‍CONFIRMATION OF FINANCIAL GUIDANCE 2017​.  Full Article

Medigene submits CTA for its first TCR clinical trial
Monday, 10 Jul 2017 09:35am EDT 

July 10 (Reuters) - MEDIGENE AG :PTA-ADHOC: MEDIGENE AG: MEDIGENE SUBMITS CTA FOR ITS FIRST TCR CLINICAL TRIAL AND ANNOUNCES MILESTONE PAYMENT.EXPECTS TO START THIS TRIAL BY YEAR END 2017.SUBMISSION TRIGGERS FINAL MILESTONE PAYMENT OF EUR 2.0 MILLION FROM MEDIGENE TO FORMER CONTRIBUTING SHAREHOLDERS OF MEDIGENE IMMUNOTHERAPIES GMBH WITHIN NEXT FIVE MONTHS.INTENDS TO SETTLE THIS PAYMENT THROUGH ISSUANCE OF NEW SHARES FROM AUTHORIZED CAPITAL.  Full Article

Medigene sticks with guidance after Q1 operating loss
Thursday, 11 May 2017 01:30am EDT 

May 11 (Reuters) - Medigene AG :Total Q1 revenue of eur 2,609 k.EBITDA loss increased as planned to eur 3,020 k.Cash and cash equivalents of eur 48,045 k on 3/31/2017.Financial guidance for 2017 confirmed.  Full Article

Medigene COO steps down
Thursday, 11 May 2017 01:28am EDT 

May 11 (Reuters) - Medigene AG :Says Dave Lemus steps down as COO and continues cooperation in an advisory role.  Full Article

BRIEF -Medigene Raises 2018 Guidance After H1 Results

* NOW EXPECTS TO GENERATE TOTAL 2018 REVENUE OF BETWEEN EUR 9.5 - 10.5 MILLION